Cargando…
Combined plasma levels of IL‐10 and testosterone, but not soluble HLA‐G5, predict the risk of death in COVID‐19 patients
BACKGROUND: The identification of biomarkers correlated with coronavirus disease 2019 (COVID‐19) outcomes is a relevant need for clinical management. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection is characterized by elevated interleukin (IL)‐6, IL‐10, HLA‐G, and impaired tes...
Autores principales: | Amodio, Giada, Capogrosso, Paolo, Pontillo, Marina, Tassara, Michela, Boeri, Luca, Carenzi, Cristina, Cignoli, Daniele, Ferrara, Anna Maria, Ramirez, Giuseppe A., Tresoldi, Cristina, Locatelli, Massimo, Santoleri, Luca, Castagna, Antonella, Zangrillo, Alberto, De Cobelli, Francesco, Tresoldi, Moreno, Landoni, Giovanni, Rovere‐Querini, Patrizia, Ciceri, Fabio, Montorsi, Francesco, Salonia, Andrea, Gregori, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877736/ https://www.ncbi.nlm.nih.gov/pubmed/36323494 http://dx.doi.org/10.1111/andr.13334 |
Ejemplares similares
-
Inverse correlation between central hypogonadism and circulating IL-10 levels in males with severe COVID-19
por: Amodio, G., et al.
Publicado: (2021) -
Severely low testosterone in men with COVID-19: A case-control study
por: Capogrosso, P., et al.
Publicado: (2021) -
Acute Kidney Injury at Hospital Admission for SARS-CoV-2 Infection as a Marker of Poor Prognosis: Clinical Implications for Triage Risk Stratification
por: Bravi, Carlo Andrea, et al.
Publicado: (2022) -
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
por: Cavalli, Giulio, et al.
Publicado: (2021) -
Infertile men with semen parameters above WHO reference limits at first assessment may deserve a second semen analysis: Challenging the guidelines in the real-life scenario
por: Boeri, Luca, et al.
Publicado: (2023)